Oxford Gene Technology SureSeq Solid Tumour Panel

Oxford Gene Technology (OGT) has launched the SureSeq Solid Tumour Panel. Fully validated on formalin-fixed, paraffin-embedded (FFPE) samples, the 60-gene, next-generation sequencing, hybridisation-based enrichment panel offers researchers solid tumour profiling for both known and novel variants.

The content of the panel covers key genes for a range of cancer types including breast, prostate, ovarian, lung and colorectal. All exons of these genes are fully covered, including mutation hotspots, enabling both detection and discovery of known and novel variants respectively.

The panel minimises PCR bias and duplications commonly associated with alternative enrichment methodologies, enabling greater run-to-run consistency. This is important in situations where there is limited sample or where the ability to detect minor allele frequencies is required, such as in heterogeneous tumour samples. Such sample types require uniform and sensitive enrichment and OGT’s expert bait design ensures this by providing efficient uniformity of coverage of the targeted regions, enabling all variants to be called with maximum confidence.

Providing easy access to meaningful data, the panel comes with the company’s Variant Analysis Report, equipping researchers with the freedom to explore and retrospectively interrogate data with additional or new selection criteria, without the need for additional in-house bioinformatics resource. Using the report, data can be filtered by numerous parameters, including gene, depth of coverage, somatic variants and predicted effect on the protein. In addition, all variants are fully annotated with links to various databases.